Evidence map›Paper›PMID 39920086›Full record

ArticleACS chemical biology2025

Alternative Approach to Sequence-Specific Recognition of DNA: Cooperative Stacking of Dication Dimers─Sensitivity to Compound Curvature, Aromatic Structure, and DNA Sequence.

Ananya Paul, J Ross Terrell, Abdelbasset A Farahat, Edwin N Ogbonna, Arvind Kumar, David W Boykin, Stephen Neidle, W David Wilson

Abstract read
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ananya PaulDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.ORCID 0000-0003-4592-3442
J Ross TerrellDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.
Abdelbasset A FarahatDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.
Edwin N OgbonnaDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.
Arvind KumarDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.
David W BoykinDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.
Stephen NeidleSchool of Pharmacy, University College London, London WC1N 1AX, U.K.ORCID 0000-0003-0622-6548
W David WilsonDepartment of Chemistry and Center for Diagnostics and Therapeutics Georgia State University, Atlanta, Georgia 30303, United States.ORCID 0000-0001-5225-5089

Funding

Molecular Design for Specific Recognition of Functional DNA SequencesR01GM111749 · NIGMS · GEORGIA STATE UNIVERSITY · PI WILSON, W DAVID · 2014 to 2021
$2.5M
NIGMS NIH HHS R01 GM111749
6 · The paper itself

Abstract

With the growing number and diversity of known genome sequences, there is an increasing opportunity to regulate gene expression through synthetic, cell-permeable small molecules. Enhancing the DNA sequence recognition abilities of minor groove compounds has the potential to broaden their therapeutic applications with significant implications for areas such as modulating transcription factor activity. While various classes of minor groove binding agents can selectively identify pure AT and mixed AT and GC base pair(s) containing sequences, there remains a lack of compounds capable of distinguishing between different AT sequences. In this work, we report on the design compounds that exhibit selective binding to -TTAA- or -TATA- containing DNA minor groove sequences compared with other AT ones. Several studies have shown that the -AATT- and -TTAA- sequences have distinct physical and interaction properties, especially in terms of their different requirements for recognition in the minor groove. Achieving strong, selective minor groove binding at -TTAA- sequences has been challenging, but DB1003, a benzimidazole-furan-furan diamidine, has demonstrated cooperative dimeric binding activity at -TTAA-. It has significantly less binding preference for AATT. To better understand and modify the selectivity, we synthesized a set of rationally designed analogs of DB1003 by altering the position of the five-membered heterocyclic structure. Binding affinities and stoichiometries obtained from biosensor-surface plasmon resonance experiments show that DB1992, a benzimidazolefuran-thiophene diamidine, binds strongly to -TTAA- as a positive cooperative dimer with high cooperativity. The high-resolution crystal structure of the TTAA-DNA-DB1992 complex reveals that DB1992 binds as an antiparallel π-stacked dimer with numerous diverse contacts to the DNA minor groove. This distinctive binding arrangement and the properties of diamidines at the -TTAA- minor groove demonstrate that benzimidazole-furan-thiophene is a unique DNA binding pharmacophore. Competition mass spectroscopy and circular dichroism studies confirmed the binding stoichiometry and selectivity preference of the compounds for the -TTAA- sequence.

Indexed as

DNABase SequenceBenzimidazolesDimerizationFuransNucleic Acid ConformationBenzimidazolesDNAFurans

Identifiers

PMID39920086
PMCPMC11851451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.